Overview

Alzheimer’s Disease Diagnostic Market is poised to value at a CAGR of over 6.2% during the forecast period 2022 to 2028.

It has been found that Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly. In recent years, the number of Alzheimer's disease cases has skyrocketed around the world, which stresses the necessity for cultivating useful drugs to treat it. The growing number of old people around the world is a primary factor fueling the growth of the Alzheimer's disease diagnostic market in years to come. Growing life expectancy is causing a rapid rise in the number of elderly people and is connected to the increase in chronic diseases such as dementia. Despite these factors, factors such as the limited recognition of Alzheimer's disease's key causes and mechanisms, and the high costs associated with diagnosis, are likely to hamper the growth of the Alzheimer's disease diagnostic market. Further, Alzheimer's disease treatments provide temporary and unclear improvements in the comfort of individuals, and there are no approved drugs that can alter the pattern of the disease's development. The growth of the Alzheimer's disease diagnostic market is thus a lucrative opportunity for drug manufacturers. Diagnostic facilities are one of the most significant obstacles preventing patients with Alzheimer's dementia from receiving basic care, which is a huge challenge for the growth of the Alzheimer's disease diagnostic market. The lack of skilled medical specialists in developing countries is another problem. The lack of knowledge regarding the new treatments used to treat Alzheimer's disease also poses a substantial challenge to the growth of the global Alzheimer's disease diagnostics market.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Alzheimer’s Disease Diagnostic Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Alzheimer’s Disease Diagnostic Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Alzheimer’s Disease Diagnostic Market:
• TauRx
• Alector LLC
• Eli Lilly and Company
• Treventis Corporation
• Neuro-Bio Ltd
• Accera, Inc.
• Cognition Therapeutics Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Quanterix
• Sysmex
• Novartis AG
• Allergan PLC
• C2N Dignostics
• Randox Bioscience
• GE Healthcare
• MAGQU CO. LTD.
• Hitachi
(Note: The list of the major players will be updated with the latest market scenario and trends)

Alzheimer’s Disease Diagnostic Market Segmentation:
By Product Type
• Brain Imaging
• CFS Test for Alzheimer's Disease
By Type  
• Early-Onset
• Late-Onset
• Familial
By End-Use
• Hospitals
• Specialty Clinics/ Diagnostic Centers
• Ambulatory Surgical Centers
• Academic & Research Institutes
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Alzheimer’s Disease Diagnostic Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Alzheimer’s Disease Diagnostic Market By Product Type, By Type, By End-Use and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Alzheimer’s Disease Diagnostic Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Alzheimer’s Disease Diagnostic Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Alzheimer’s Disease Diagnostic Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Alzheimer’s Disease Diagnostic Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Brain Imaging
   7.2. CFS Test for Alzheimer's Disease

8. Alzheimer’s Disease Diagnostic Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Early-Onset
   8.2. Late-Onset
   8.3. Familial

9. Alzheimer’s Disease Diagnostic Market, By End-Use Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospitals
   9.2. Specialty Clinics/ Diagnostic Centers
   9.3. Ambulatory Surgical Centers
   9.4. Academic & Research Institutes

10. North America Alzheimer’s Disease Diagnostic Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Alzheimer’s Disease Diagnostic Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Alzheimer’s Disease Diagnostic Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Alzheimer’s Disease Diagnostic Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   16.1. TauRx
         16.1.1. Company Overview
         16.1.2. Product Portfolio
         16.1.3. SWOT Analysis
         16.1.4. Financial Overview
         16.1.5. Strategic Overview
   16.2. Alector LLC
         16.2.1. Company Overview
         16.2.2. Product Portfolio
         16.2.3. SWOT Analysis
         16.2.4. Financial Overview
         16.2.5. Strategic Overview
   16.3. Eli Lilly and Company
         16.3.1. Company Overview
         16.3.2. Product Portfolio
         16.3.3. SWOT Analysis
         16.3.4. Financial Overview
         16.3.5. Strategic Overview
   16.4. Treventis Corporation
         16.4.1. Company Overview
         16.4.2. Product Portfolio
         16.4.3. SWOT Analysis
         16.4.4. Financial Overview
         16.4.5. Strategic Overview
   16.5. Neuro-Bio Ltd
         16.5.1. Company Overview
         16.5.2. Product Portfolio
         16.5.3. SWOT Analysis
         16.5.4. Financial Overview
         16.5.5. Strategic Overview          
   16.6. Accera, Inc.
         16.6.1. Company Overview
         16.6.2. Product Portfolio
         16.6.3. SWOT Analysis
         16.6.4. Financial Overview
         16.6.5. Strategic Overview      
   16.7. Cognition Therapeutics Inc.
         16.7.1. Company Overview
         16.7.2. Product Portfolio
         16.7.3. SWOT Analysis
         16.7.4. Financial Overview
         16.7.5. Strategic Overview
   16.8. Johnson & Johnson
         16.8.1. Company Overview
         16.8.2. Product Portfolio
         16.8.3. SWOT Analysis
         16.8.4. Financial Overview
         16.8.5. Strategic Overview
   16.9. F. Hoffmann-La Roche Ltd
         16.9.1. Company Overview
         16.9.2. Product Portfolio
         16.9.3. SWOT Analysis
         16.9.4. Financial Overview
         16.9.5. Strategic Overview
   16.10.Quanterix
         16.10.1. Company Overview
         16.10.2. Product Portfolio
         16.10.3. SWOT Analysis
         16.10.4. Financial Overview
         16.10.5. Strategic Overview
   16.11.Sysmex
         16.11.1. Company Overview
         16.11.2. Product Portfolio
         16.11.3. SWOT Analysis
         16.11.4. Financial Overview
         16.11.5. Strategic Overview
   16.12.Novartis AG
         16.12.1. Company Overview
         16.12.2. Product Portfolio
         16.12.3. SWOT Analysis
         16.12.4. Financial Overview
         16.12.5. Strategic Overview
   16.13.Allergan PLC
         16.13.1. Company Overview
         16.13.2. Product Portfolio
         16.13.3. SWOT Analysis
         16.13.4. Financial Overview
         16.13.5. Strategic Overview
   16.14.C2N Dignostics
         16.14.1. Company Overview
         16.14.2. Product Portfolio
         16.14.3. SWOT Analysis
         16.14.4. Financial Overview
         16.14.5. Strategic Overview
   16.15.Randox Bioscience
         16.15.1. Company Overview
         16.15.2. Product Portfolio
         16.15.3. SWOT Analysis
         16.15.4. Financial Overview
         16.15.5. Strategic Overview
   16.16.GE Healthcare
         16.16.1. Company Overview
         16.16.2. Product Portfolio
         16.16.3. SWOT Analysis
         16.16.4. Financial Overview
         16.16.5. Strategic Overview
   16.17.MAGQU CO. LTD.
         16.17.1. Company Overview
         16.17.2. Product Portfolio
         16.17.3. SWOT Analysis
         16.17.4. Financial Overview
         16.17.5. Strategic Overview 
   16.18.Hitachi
         16.18.1. Company Overview
         16.18.2. Product Portfolio
         16.18.3. SWOT Analysis
         16.18.4. Financial Overview
         16.18.5. Strategic Overview 

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures